100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
Previously searched by you
Previously searched by you
logo
Summary BNF Drug Summaries - Cardiovascular System $7.12   Add to cart
Quickly navigate to
Preview
  2.  
  3. Pharmacy
  4.  
  5. Pharmacy
  6.  
  7. Pharmacy

Summary

Summary BNF Drug Summaries - Cardiovascular System

1 review
 159 views  1 purchase
  • Course
  • Pharmacy
  • Institution
  • Pharmacy
  • Book
  • BNF 81 (British National Formulary) March 2021

A 14-page concise summary of the cardiovascular system intended to facilitate preparation for the GPhC registration exam. These notes can also be used as a quick reference guide or a resource to refresh general clinical pharmacy knowledge, perfect for pre-registration pharmacists, medical students,...

[Show more]

Preview 2 out of 14  pages

Document information

  • No
  • Chapter 2 - cardiovascular system
  • June 8, 2021
  • 14
  • 2020/2021
  • Summary

Subjects

  • bnf
  • drug
  • summaries
  • cardiovascular
  • system
  • pharmacology
  • medicines
  • arrhythmias
  • amiodarone
  • digoxin
  • venous
  • thromboembolism
  • stroke
  • aspirin
  • oral
  • antiplatelet
  • hypertension
  • antihypertensive
  • heart
  • failure
  • lipid

Connected book

book image

Book Title:

Author(s):

  • Edition:
  • ISBN:
  • Edition:

More summaries for

  • BNF Drug Summaries - Emergency Treatment of Poisoning
  • BNF Drug Summaries - Malignant Disease
  • BNF Drug Summaries - Respiratory System
All for this textbook (5)

Written for

  • Pharmacy
  • pharmacy
  • Pharmacy
All documents for this subject (239)

1  review

review-writer-avatar

By: ti2651999 • 2 year ago

Seller

avatar-seller
humzaibrahim

Reviews received

Content preview

Drug Summaries – Humza Ibrahim
4.2.2 Long-term management ...................... 6
Chapter 2 5 Warfarin (high risk) .............................................. 7
Cardiovascular System 5.1 Target inr...................................................... 7
5.2 Duration ....................................................... 7

TABLE OF CONTENTS 5.3 Warning sings............................................... 7
5.4 Monitoring ................................................... 7
Table of Contents ......................................................... 1
5.5 Pregnancy and breastfeeding ...................... 7
1 Arrhythmias.......................................................... 3
5.6 Interactions .................................................. 7
1.1 Drugs for arrhythmias .................................. 3
5.7 Hepatic impairment ..................................... 7
1.1.1 Drug treatment .................................... 3
5.8 Renal impairment ........................................ 7
1.1.2 Cardioversion ....................................... 3
5.9 Other points ................................................. 7
1.1.3 Stroke prevention ................................ 3
6 Antiplatelet drugs ................................................ 8
1.2 Amiodarone (high risk)................................ 4
6.1 Aspirin .......................................................... 8
1.2.1 Warning signs ....................................... 4
6.1.1 Reye's syndrome (liver and brain
1.2.2 Monitoring ........................................... 4 damage) 8
1.2.3 Pregnancy............................................. 4 6.1.2 Hypersensitivity ................................... 8
1.2.4 Breastfeeding ....................................... 4 6.2 Oral antiplatelets (high risk) ....................... 8
1.2.5 Drug Interactions ................................. 4 6.2.1 Warning signs....................................... 8
1.3 Sotalol .......................................................... 4 6.2.2 Monitoring ........................................... 8
1.3.1 Safety information ............................... 4 6.2.1 Other points ......................................... 8
1.3.2 Monitoring ........................................... 4 6.2.2 Interactions .......................................... 8
2 Cardiac Glycosides ............................................... 5 7 Hypertension ....................................................... 8
2.1 Digoxin (High Risk)....................................... 5 7.1 Thresholds.................................................... 8
2.1.1 Warning signs ....................................... 5 7.2 Targets for treatment .................................. 9
2.1.2 Monitoring ........................................... 5 7.3 Drug treatment (NICE 2107) ........................ 9
2.1.3 Renal impairment................................. 5 7.4 Reducing cardiovascular risk........................ 9
2.1.4 Drug interactions.................................. 5 7.5 Diabetes and renal disease .......................... 9
3 Venous Thromboembolism .................................. 5 7.6 Hypertension and pregnancy....................... 9
3.1 Prophylaxis ................................................... 5 7.7 Hypertensive crisis ....................................... 9
3.2 Treatment .................................................... 5 7.8 Antihypertensives (high risk) ...................... 9
3.3 Pregnancy..................................................... 5 7.8.1 Warning signs....................................... 9
3.4 Haemorrhage ............................................... 6 7.8.2 Monitoring ........................................... 9
3.5 Heparin......................................................... 6 7.8.3 Interactions .......................................... 9
3.5.1 Heparin-induced thrombocytopenia ... 6 7.8.4 Other points ......................................... 9
3.5.2 Hyperkalaemia ..................................... 6 7.9 Drugs affecting the renin-angiotensin
4 Stroke ................................................................... 6 system 10

4.1 Transient ischaemic attack........................... 6 7.9.1 Initiation under specialist supervision10

4.2 Ischaemic stroke .......................................... 6 7.9.2 Renal effects ...................................... 10

4.2.1 Initial management .............................. 6 7.9.3 Cautions ............................................. 10
7.10 Beta-adrenoceptor blocking drugs ............ 10
Chapter 2 – Pg 1
Compiled using the British National Formulary

, Drug Summaries – Humza Ibrahim
7.11 Calcium channel blockers........................... 11
7.12 Hypotension and shock .............................. 11
8 Heart failure ....................................................... 11
9 Hyperlipidaemia ................................................. 11
9.1 Risk calculators........................................... 11
9.2 Primary and secondary prevention of
cardiovascular disease ........................................... 11
9.3 Cholesterol tests ........................................ 12
9.4 Hypercholesterolaemia,
hypertriglyceridaemia, and familial
hypercholesterolaemia .......................................... 12
9.5 Statins......................................................... 12
10 Stable angina ...................................................... 12
11 Acute coronary syndromes (ACS) ...................... 12
11.1 Initial management of unstable angina,
nstemi and stemi.................................................... 12
11.1.1 Additional acute management of
unstable angina, NSTEMI ................................... 13
11.1.2 Additional acute management of STEMI
13
11.2 Long-term management ACS ..................... 13
11.3 Nitrates....................................................... 13
11.4 Fibrinolytics ................................................ 13
12 Oedema .............................................................. 13
12.1 Elderly ........................................................ 13
12.2 Potassium loss ............................................ 13
12.3 Urinary retention ....................................... 13
12.4 Diabetes and gout ...................................... 13
12.5 Diuretics (high risk).................................... 14
12.5.1 Warning signs ..................................... 14
12.5.2 Monitoring ......................................... 14
12.5.3 Other points ....................................... 14
12.5.4 Interactions ........................................ 14




Chapter 2 – Pg 2
Compiled using the British National Formulary

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller humzaibrahim. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $7.12. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

77254 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling
$7.12  1x  sold
  • (1)
  Add to cart